Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 428

The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

Open access
Wang, Feng‐Hua, Zhang, Xiao‐Tian, Tang, Lei, Wu, Qi, Cai, Mu‐Yan, Li, Yuan‐Fang, Qu, Xiu‐Juan, Qiu, Hong, Zhang, Yu‐Jing, Ying, Jie‐Er, Zhang, Jun, Sun, Ling‐Yu, Lin, Rong‐Bo, Wang, Chang, Liu, Hao, Qiu, Miao‐Zhen, Guan, Wen‐Long, Rao, Sheng‐Xiang, Ji, Jia‐Fu, Xin, Yan, Sheng, Wei‐Qi, Xu, Hui‐Mian, Zhou, Zhi‐Wei, Zhou, Ai‐Ping, Jin, Jing, Yuan, Xiang‐Lin, Bi, Feng, Liu, Tian‐Shu, Liang, Han, Zhang, Yan‐Qiao, Li, Guo‐Xin, Liang, Jun, Liu, Bao‐Rui, Shen, Lin, Li, Jin, Xu, Rui‐Hua·2024·Cancer Communications

Abstract

The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence‐based medicine, healthcare resource availability, and precision medicine. These updates address the differences in epidemiological characteristics, clinicopathological features, tumor biology, treatment patterns, and drug selections between Eastern and Western gastric cancer patients. Key revisions include a structured template for imaging diagnosis reports, updated standards for molecular marker testing in pathological diagnosis, and an elevated recommendation for neoadjuvant chemotherapy in stage III gastric cancer. For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti‐angiogenic therapy and targeted drugs, along with updated management strategies for human epidermal growth factor receptor 2 (HER2)‐positive and deficient DNA mismatch repair (dMMR)/microsatellite instability‐high (MSI‐H) patients. Additionally, the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer. The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice, particularly in the heterogeneous healthcare landscape of China, while maintaining a commitment to scientific rigor, impartiality, and timely revisions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cac2.12516

Cites

155 of 155 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 155 references

Metadata

Authors
Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., Zhang, J., Sun, L., Lin, R., Wang, C., Liu, H., Qiu, M., Guan, W., Rao, S., Ji, J., Xin, Y., Sheng, W., Xu, H., Zhou, Z., Zhou, A., Jin, J., Yuan, X., Bi, F., Liu, T., Liang, H., Zhang, Y., Li, G., Liang, J., Liu, B., Shen, L., Li, J., & Xu, R.
Venue
Cancer Communications
Published
2023-12-31
Volume
44
Issue
1
Pages
127-172
ISSN
  • 1000-467X (ISSN-L)
  • 2523-3548
OpenAlex
W4390469429
Cited by
428
References
155
FWCI
61.48
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. https://app.cochat.ai/papers/10.1002/cac2.12516
The paper
Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., Zhang, J., Sun, L., Lin, R., Wang, C., Liu, H., Qiu, M., Guan, W., Rao, S., Ji, J., . . . Xu, R. (2024). The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Communications. https://doi.org/10.1002/cac2.12516

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.